Antisense ATM gene therapy: A strategy to increase the radiosensitivity of human tumors

Gene Therapy

Volumn 7, Issue 10, 2000, Pages 852-858

  Guha, C ^a,d   Guha, U ^a   Tribius, S ^a   Alfieri, A ^b   Casper, D ^a   Chakravarty, P ^a   Mellado, W ^c   Pandita, T K ^c   Vikram, B ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c Howard Hughes Medical Institute   (United States)

^d Department of Radiation Oncology ^*  (United States)

Author keywords

Antisense gene therapy; ATM; Glioblastoma multiforme; Radiation therapy

Indexed keywords

COMPLEMENTARY RNA; PROTEIN P21; PROTEIN P53;

ARTICLE; ATAXIA TELANGIECTASIA; CANCER; DNA DAMAGE; DNA SYNTHESIS; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0034064978     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301174     Document Type: Article

References (34)

1. Taylor AM et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 1975; 258: 427-429.
2. Gatti RA et al. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 1991; 70: 99-117.
3. Beamish H, Lavin MF. Radiosensitivity in ataxia-telangiectasia: anomalies in radiation-induced cell cycle delay. Int J Radiat Biol 1994; 65: 175-184.
4. Kastan MB et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
5. Painter RB, Young BR. Radiosensitivity in ataxia-telangiectasia: a new explanation. Proc Natl Acad Sci USA 1980; 77: 7315-7317.
6. Savitsky K et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase (see comments). Science 1995; 268: 1749-1753.
7. Morgan SE et al. Fragments of ATM which have dominant-negative or complementing activity. Molec Cell Biol 1997; 17: 2020-2029.
8. Barlow C et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996; 86: 159-171.
9. Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control (see comments). Genes Dev 1996; 10: 2401-2410.
10. Khanna KK et al. Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. Oncogene 1995; 11: 609-618.
11. Banin S et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 281: 1674-1677.
12. Canman CE et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281: 1677-1679.
13. Westphal CH et al. Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res 1998; 58: 5637-5639.
14. Herzog KH et al. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998; 280: 1089-1091.
15. Barlow C et al. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet 1997; 17: 453-456.
16. Young BR, Painter RB. Radioresistant DNA synthesis and human genetic diseases. Hum Genet 1989; 82: 113-117.
17. Haas-Kogan DA et al. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 1996; 36: 95-103.
18. Yount GL et al. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res 1996; 56: 500-506.
19. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491-7495.
20. Kastan MB et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
21. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
22. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 1998; 19: 175-178.
23. Xu Y et al. Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm-/- mice. Mol Cell Biol 1998; 18: 4385-4390.
24. Gosink EC, Chong MJ, McKinnon PJ. Ataxia telangiectasia mutated deficiency affects astrocyte growth but not radiosensitivity. Cancer Res 1999; 59: 5294-5298.
25. West CM, Davidson SE, Roberts SA, Hunter RD. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 1993; 68: 819-823.
26. West CM, Davidson SE, Roberts SA, Hunter, RD. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997; 76: 1184-1190.
27. Kelland LR, Steel, GG. Recovery from radiation damage in human squamous carcinoma of the cervix. Int J Radiat Biol 1989; 55: 119-127.
28. Taghian A et al. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1993; 25: 243-249.
29. Kim JH, Kim SH, Brown SL, Freytag SO. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 1994; 54: 6053-6056.
30. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
31. Hallahan DE et al. Spatial and temporal control of gene therapy using ionizing radiation. Nature Med 1995; 1: 786-791.
32. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
33. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968; 74: 465-486.
34. Harlow E, Lane D (eds). Immunoblotting. In: Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Plainview, NY, 1988 pp 471-510.